Natco Pharma Limited (NATCOPHARM) announced that the Board of Directors approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026. The meeting commenced at 11:45 a.m. and concluded at 2:05 p.m.
Consolidated results include the parent company, thirteen subsidiaries and step-down subsidiaries, and associate Adcock Ingram Holdings Limited. Subsidiaries reported aggregate total revenue of Rs 711 crore and net profit after tax of Rs 136.5 crore for the fiscal year ended March 2026. The Group's share of net profit from associate Adcock Ingram Holdings stood at Rs 46.6 crore.
The Board approved amendments to the Corporate Social Responsibility Policy and the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. The updated policies have been published on the Natco Pharma website.
Natco Pharma incorporated NATCO Pharma South Africa Proprietary Limited in July 2025 and NATCO Crop Health Sciences Limited in India in December 2025. Adcock Ingram Holdings Limited, based in South Africa, became an associate of Natco Pharma effective November 2025.
Financial statements cover operations across subsidiaries in the United States, Brazil, Canada, Singapore, Australia, the Philippines, the United Kingdom, Indonesia, and Colombia. The detailed financial statements and press release have been submitted to the stock exchanges.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.